These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24231212)

  • 21. Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation.
    Whitson JM; Cooperberg MR; Stackhouse GB; Stoller ML
    Urology; 2007 Oct; 70(4):634-7. PubMed ID: 17991528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
    Pak CY; Peterson R
    Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary citrate in kidney stone disease.
    Usui Y; Matsuzaki S; Matsushita K; Shima M
    Tokai J Exp Clin Med; 2003 Jul; 28(2):65-70. PubMed ID: 14714831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic effects of Orthosiphon stamineus Benth. extracts on experimental induction of calcium oxalate nephrolithiasis in rats.
    Zhong YS; Yu CH; Ying HZ; Wang ZY; Cai HF
    J Ethnopharmacol; 2012 Dec; 144(3):761-7. PubMed ID: 23123267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic syndrome in obese adolescents is associated with risk for nephrolithiasis.
    Tiwari R; Campfield T; Wittcopp C; Braden G; Visintainer P; Reiter EO; Allen HF
    J Pediatr; 2012 Apr; 160(4):615-620.e2. PubMed ID: 22099686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation.
    Koff SG; Paquette EL; Cullen J; Gancarczyk KK; Tucciarone PR; Schenkman NS
    Urology; 2007 Jun; 69(6):1013-6. PubMed ID: 17572176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors increasing the risk for stone formation in adult patients with cystic fibrosis.
    Terribile M; Capuano M; Cangiano G; Carnovale V; Ferrara P; Petrarulo M; Marangella M
    Nephrol Dial Transplant; 2006 Jul; 21(7):1870-5. PubMed ID: 16595587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis.
    Kang DE; Sur RL; Haleblian GE; Fitzsimons NJ; Borawski KM; Preminger GM
    J Urol; 2007 Apr; 177(4):1358-62; discussion 1362; quiz 1591. PubMed ID: 17382731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Citrate and renal calculi: an update.
    Pak CY
    Miner Electrolyte Metab; 1994; 20(6):371-7. PubMed ID: 7783699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis.
    He Y; Chen X; Yu Z; Wu D; Lv Y; Shi S; Zhu H
    J Nephrol; 2004; 17(1):34-42. PubMed ID: 15151257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concrement formation and urease-induced crystallization in urine from patients with continent ileal reservoirs.
    Edin-Liljegren A; Grenabo L; Hedelin H; Jonsson O; Akerlund S; Pettersson S
    Br J Urol; 1996 Jul; 78(1):57-63. PubMed ID: 8795401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
    Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary pH and stone formation.
    Wagner CA; Mohebbi N
    J Nephrol; 2010; 23 Suppl 16():S165-9. PubMed ID: 21170875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes.
    Bell DS
    Diabetes Obes Metab; 2012 Apr; 14(4):299-303. PubMed ID: 21992452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation.
    Penniston KL; Steele TH; Nakada SY
    Urology; 2007 Nov; 70(5):856-60. PubMed ID: 17919696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
    Pak CY; Koenig K; Khan R; Haynes S; Padalino P
    J Bone Miner Res; 1992 Mar; 7(3):281-5. PubMed ID: 1585829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.
    Mohkam M; Karimi A; Gharib A; Daneshmand H; Khatami A; Ghojevand N; Sharifian M
    Pediatr Nephrol; 2007 May; 22(5):690-4. PubMed ID: 17226043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.